Oral MEK 1/2 Inhibitor Trametinib in Combination with AKT Inhibitor GSK2141795 in Patients with Acute Myeloid Leukemia with RAS Mutations: A Phase II Study

With proven single-agent activity and favorable toxicity profile of MEK-1/2 inhibition in advanced leukemia, investigation into combination strategies to overcome proposed resistance pathways is warranted. Resistance to MEK inhibition is secondary to upstream hyperactivation of RAS/RAF or activation...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Lymphoma Myeloma Leuk
Glavni autori: Ragon, Brittany Knick, Odenike, Olatoyosi, Baer, Maria R, Stock, Wendy, Borthakur, Gautam, Patel, Keyur, Han, Lina, Chen, Helen, Ma, Helen, Joseph, Loren, Zhao, Yang, Baggerly, Keith, Konopleva, Marina, Jain, Nitin
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6626580/
https://ncbi.nlm.nih.gov/pubmed/31056348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2019.03.015
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items